01—Abstract
Summary
Summary of the 10-K filed February 19, 2016. Cited figures are marked; the original filing is the authoritative source.
Edwards Lifesciences Corporation's 2015 10-K report highlights a year of significant growth, particularly driven by its Transcatheter Heart Valve Therapy (THV) segment.
THV sales increased by 25.1% year-over-year, reaching $1.18 billiona, largely due to the successful launches of the Edwards SAPIEN XT and SAPIEN 3 valves in key markets like the US and Europe. Despite this growth, the company's Surgical Heart Valve Therapy segment experienced a slight decline of 5.0% in net sales, impacted by foreign currency fluctuations. Overall, net sales grew by 7.4% to $2.49 billion, with net income experiencing a significant decrease of 39.0% to $494.9 million, primarily due to a substantial $750 million upfront payment received from Medtronic in 2014 as part of a litigation settlement, which boosted the prior year's net income.
The company continues to invest heavily in research and development, allocating 15.4% of its net sales to drive innovation in structural heart disease and critical care. Financially, Edwards Lifesciences maintained a strong balance sheet with total assets of $4.06 billionb. The company also repurchased $275 million of its common stock in 2015 and has significant capacity under its existing repurchase programs.
Management's focus remains on expanding its leadership in THV, including advancements in mitral and tricuspid valve technologies, and generating robust clinical and economic evidence to support new therapies. The report also details various risk factors, including intense competition, regulatory hurdles, and potential supply chain disruptions, alongside market risks related to economic conditions and currency fluctuations.
02—Key points
Key Highlights
- Transcatheter Heart Valve Therapy (THV) sales grew 25.1% to $1.18 billion, driven by the SAPIEN XT and SAPIEN 3 valve launches.
- Total net sales increased 7.4% to $2.49 billion.
- Net income decreased 39.0% to $494.9 million, impacted by a large litigation settlement payment received in the prior year.
- Research and Development (R&D) spending was 15.4% of net sales ($383.1 million), reflecting a commitment to innovation.
- The company acquired CardiAQ Valve Technologies, a developer of a transcatheter mitral valve replacement system, for $350 million.
- The company continued its share repurchase program, repurchasing $275 million of common stock during the year.
- The stock price showed significant appreciation throughout 2015, ending the year at $83.43 (post-split), an increase of over 80% from the beginning of the year.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-KFY2015filed February 19, 2016Financial Statements
FY2015 against FY2014
| Line item | FY2015FY2014 | Change |
|---|---|---|
| Revenue | $2.49B$2.32B | +7.4% |
| Cost of Revenue | $617.20M$625.60M | −1.3% |
| Gross Profit | $1.88B$1.70B | +10.6% |
| R&D Expenses | $382.90M$346.50M | +10.5% |
| SG&A Expenses | $850.70M$858.00M | −0.9% |
| Interest Expense | $17.20M$17.20M | 0.0% |
| Net Income | $494.90M$811.10M | −39.0% |
| EPS (Basic) | $0.77$1.27 | −39.6% |
| EPS (Diluted) | $0.75$1.25 | −39.8% |
| Shares Outstanding (Basic) | 646.50M639.00M | +1.2% |
| Shares Outstanding (Diluted) | 660.90M651.00M | +1.5% |
05—Questions
Frequently Asked Questions
What drove the significant increase in Edwards Lifesciences' stock price in 2015?
The company's stock price saw substantial growth in 2015, largely driven by the strong performance of its Transcatheter Heart Valve (THV) segment, successful product launches (SAPIEN XT and SAPIEN 3), and strategic acquisitions like CardiAQ. Positive clinical data and continued investment in R&D also contributed to investor confidence.
Why did net income decrease in 2015 despite revenue growth?
The decrease in net income was primarily due to a one-time $750 million upfront payment received from Medtronic in 2014 as part of a litigation settlement. This payment significantly boosted net income in the prior year, making the year-over-year comparison appear lower in 2015, despite underlying operational growth.
How is the company positioning itself for future growth in valve therapies?
Edwards Lifesciences is heavily investing in R&D and strategic acquisitions to expand its leadership in structural heart disease. The acquisition of CardiAQ Valve Technologies is a key step in developing transcatheter mitral valve replacement systems, addressing a significant unmet need. The company is also focused on developing next-generation THV technologies and expanding indications for existing products.
What are the main risks highlighted in the report for Edwards Lifesciences?
Key risks include intense competition in the medical device industry, the need for timely new product introductions to avoid obsolescence, reliance on third-party payor reimbursement, potential supply chain disruptions, stringent government regulations for medical devices, and risks associated with international operations, including currency fluctuations.
06—Continue